Bioo Scientific this week announced that it has received a two-year, $500,000 grant from the National Science Foundation to develop a targeted, in vivo RNAi-delivery technology.
The award, a phase II Small Business Innovation Research grant, will specifically fund Bioo Scientific's work on its so-called Targeted Transport Technology, which the company said involves linking an "RNAi-agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA and miRNA molecules.
"The RNAi agent-loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by" the antibody, Bioo Scientific added. "The RNAi agent is then released to reduce the expression of its intended target."
The company expects to use the technology to create RNAi-delivery products for use in animal research.